Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Eckert+Ziegler

Related articles:
7/23/2026 6:59:39 AM - Eckert & Ziegler: Strong Ga-68 outlook attracts competition; chg. est. & PT - NuWays AG Research - The prostate theranostics market is expanding fast. Novartis reported Pluvicto Q2 2026 sales up c. 43% yoy. Stronger therapy volumes relate to more Ga-68 PSMA PET diagnostics, often utilizing EUZ's Ga-68 generator. EUZ is benefitting from the demand, currently accounting for an estimated 60-80% of the Ga-68 generator market with its product GalliaPharm (c. 20% of group revenues).
5/13/2026 6:29:50 AM - Eckert+Ziegler: Q1 released: Medical powers ahead - NuWays AG Research - The takeaway from Eckert & Ziegler’s Q1 results is positive: Medical delivered strong underlying growth without licence revenues, while Isotope Products offers a recovery lever for the rest of the year. At group level, fx-adj. sales rose 11% yoy to € 72.9m, while reported sales rose 7% yoy. Adj. EBIT came in roughly flat yoy at € 16m, with the margin declining 1.8pp yoy to 21.9%.
4/20/2026 12:26:59 PM - Eckert+Ziegler Q1 preview: Medical to continue growth trajectory - NuWays AG Research - EUZ Q1 26 results are due on May 12. We expect sales of € 72.5m (+6% yoy) and adj. EBIT of € 16.0m (-1% yoy), implying a 22.1% margin (-1.7 pp yoy). This should mark a solid start to FY 26 with radiopharma continuing to drive the business.
2/1/2021 10:00:09 AM - Duo plockas in i Placeras lista över 15 köpvärda aktier - Placeras lista över 15 köpvärda aktier gör plats för amerikanska dataanalys- och riskhanteringsföretaget Verisk Analytics och tyska Eckert & Ziegler, tillverkare av radioaktiva isotoper.